CA2264775A1 - Methode de traitement des maladies post-menopausiques, dont l'osteoporose - Google Patents

Methode de traitement des maladies post-menopausiques, dont l'osteoporose Download PDF

Info

Publication number
CA2264775A1
CA2264775A1 CA002264775A CA2264775A CA2264775A1 CA 2264775 A1 CA2264775 A1 CA 2264775A1 CA 002264775 A CA002264775 A CA 002264775A CA 2264775 A CA2264775 A CA 2264775A CA 2264775 A1 CA2264775 A1 CA 2264775A1
Authority
CA
Canada
Prior art keywords
idoxifene
osteoporosis
estrogen
bone
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002264775A
Other languages
English (en)
Inventor
Jeremy N. Bradbeer (Deceased)
Maxine Gowen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CA2264775A1 publication Critical patent/CA2264775A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'invention concerne une nouvelle méthode destinée à traiter l'ostéoporose. L'idoxifène est le composé préféré.
CA002264775A 1996-09-06 1997-09-03 Methode de traitement des maladies post-menopausiques, dont l'osteoporose Abandoned CA2264775A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2543996P 1996-09-06 1996-09-06
US60/025,439 1996-09-06
US5066697P 1997-06-24 1997-06-24
US60/050,666 1997-06-24
PCT/US1997/015474 WO1998009519A1 (fr) 1996-09-06 1997-09-03 Methode destinee a traiter des maladies post-menopausiques, dont l'osteoporose

Publications (1)

Publication Number Publication Date
CA2264775A1 true CA2264775A1 (fr) 1998-03-12

Family

ID=26699738

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002264943A Abandoned CA2264943A1 (fr) 1996-09-06 1997-09-03 Procedes nouveaux
CA002264775A Abandoned CA2264775A1 (fr) 1996-09-06 1997-09-03 Methode de traitement des maladies post-menopausiques, dont l'osteoporose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002264943A Abandoned CA2264943A1 (fr) 1996-09-06 1997-09-03 Procedes nouveaux

Country Status (16)

Country Link
EP (2) EP0929216A4 (fr)
JP (2) JP2002515047A (fr)
KR (2) KR20000068473A (fr)
CN (2) CN1236313A (fr)
AR (1) AR008155A1 (fr)
AU (2) AU4247397A (fr)
BR (2) BR9711676A (fr)
CA (2) CA2264943A1 (fr)
CO (2) CO5070658A1 (fr)
CZ (1) CZ76699A3 (fr)
IL (1) IL128645A0 (fr)
NO (2) NO991096D0 (fr)
PL (2) PL332278A1 (fr)
TR (2) TR199900506T2 (fr)
TW (1) TW411273B (fr)
WO (2) WO1998009619A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034608A1 (fr) * 1997-02-11 1998-08-13 Novo Nordisk A/S Methodes therapeutiques ou prophylactiques a l'encontre de symptomes menopausiques
GB9827121D0 (en) * 1998-12-09 1999-02-03 Orion Corp Agent for lowering endothelin levels
DE19905961A1 (de) * 1999-02-12 2000-08-17 Stefan Neubauer Verwendung von Östrogenen zur Behandlung der Herzinsuffizienz
US6528681B2 (en) * 2000-04-05 2003-03-04 Bristol-Meyers Squibb Pharma Company Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
IL145876A0 (en) 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3762617D1 (de) * 1986-09-11 1990-06-13 Nat Res Dev Tamoxifenderivate.
CA2143000C (fr) * 1992-09-15 2000-03-28 Alan J. Bitonti Analogues non metabolisables de clomifene pour le traitement de tumeurs resistant au tamoxifene
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5470883A (en) * 1994-05-23 1995-11-28 Stromberg; Brent V. Method of treating peripheral vasoconstriction with tamoxifen citrate
ATE377418T1 (de) * 1995-06-07 2007-11-15 Poniard Pharmaceuticals Inc Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis

Also Published As

Publication number Publication date
EP0929216A4 (fr) 2001-04-04
AU4409797A (en) 1998-03-26
BR9711681A (pt) 1999-08-24
AR008155A1 (es) 1999-12-09
CO4920218A1 (es) 2000-05-29
WO1998009519A1 (fr) 1998-03-12
JP2002515047A (ja) 2002-05-21
JP2002515046A (ja) 2002-05-21
TR199900506T2 (xx) 1999-07-21
AU4247397A (en) 1998-03-26
TR199900504T2 (xx) 1999-06-21
NO991096L (no) 1999-03-05
BR9711676A (pt) 1999-08-24
CN1236299A (zh) 1999-11-24
CO5070658A1 (es) 2001-08-28
EP0929216A1 (fr) 1999-07-21
PL332278A1 (en) 1999-08-30
EP0927029A4 (fr) 2001-06-13
TW411273B (en) 2000-11-11
CZ76699A3 (cs) 1999-08-11
KR20000068472A (ko) 2000-11-25
NO991096D0 (no) 1999-03-05
CN1236313A (zh) 1999-11-24
CA2264943A1 (fr) 1998-03-12
KR20000068473A (ko) 2000-11-25
NO991097L (no) 1999-03-05
NO991097D0 (no) 1999-03-05
IL128645A0 (en) 2000-01-31
PL332038A1 (en) 1999-08-16
EP0927029A1 (fr) 1999-07-07
WO1998009619A1 (fr) 1998-03-12

Similar Documents

Publication Publication Date Title
Turken et al. Effects of tamoxifen on spinal bone density in women with breast cancer
EP1438957B1 (fr) Raloxifène destinée au traitement de l'ostéoporose post-ménopause
US5770226A (en) Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
JPH06234632A (ja) ベンゾチオフェン類を含有する医薬組成物
KR20010022956A (ko) 에스트로겐-의존성 질병 및 장애의 예방방법 또는 치료방법
CA2264775A1 (fr) Methode de traitement des maladies post-menopausiques, dont l'osteoporose
CA2223055A1 (fr) Procedes pour minimiser les pertes osseuses
Phillips Endometrial ablation for postmenopausal uterine bleeding induced by hormone replacement therapy
MXPA99002213A (en) Method of treating post menopausal diseases, including osteoporosis
EP1140047B1 (fr) Hormonotherapie du cancer du sein associee a un traitement au tamoxifene et aux dibenzofurannes polychlores alkyles
Goulding et al. Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin
EP0747056B1 (fr) Diminuer la perte osseuse par des combinaisons d'anti-estrogènes
WO1999000019A1 (fr) Procedes de traitement des symptomes de la vaginite atrophique et du comportement sexuel modifie chez des femmes postmenopausees
Goulding et al. Effects of clomiphene and tamoxifen in vivo on the bone-resorbing effects of parathyroid hormone and of high oral doses of calcitriol (1, 25 (OH) 2D3) in rats with intact ovarian function consuming low calcium diet
PL186085B1 (pl) Stosowanie antyestrogenów do kontroli płodności męskiej
Lamarca The Role of Hormone Replacement Therapy (HRT) and Tibolone in the Prevention and Treatment of Postmenopausal Osteoporosis
Whitehead Effects of Oral, Percutaneous and Transdermal Oestrogens on Postmenopausal Bone
Marcus Use of estrogen for prevention and treatment of osteoporosis
AL-GANZOURY et al. Effect of estrogen agonist antagonist on bone mineral density in postmenopausal breast cancer
WO1998049896A1 (fr) Methode de traitement de symptomes vasomoteurs
WO1999000018A1 (fr) Methodes de traitement des symptomes de troubles de la memoire, de la concentration et de la cognition chez la femme menauposee
MXPA99002214A (en) Novel methods

Legal Events

Date Code Title Description
FZDE Discontinued